This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Moderna, Inc.
11/6/2026
Good day and thank you for standing by. Welcome to Moderna's third quarter 2026 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised, today's conference is being recorded. I would like to hand the conference over to your speaker today. Lavina Talukdar, please go ahead.
Thank you, Kevin. Good morning, everyone. And thank you for joining us on today's call to discuss Moderna's third quarter 2026 financial results and business updates. You can access the press release issued this morning, as well as the slides that we'll be reviewing by going to the investor section of our website. On today's call are Stéphane Bancel, our chief executive officer, Stephen Hoge, our president, Jamie Mock, our chief financial officer, and David Berman, our Chief Development Officer. Before we begin, please note that this call will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see slide two of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. With that, I will turn the call over to Stéphane.
Thank you, Lavina. Good morning or good afternoon, everyone. Thank you for joining us. I will start today with a review of third quarter, Jimmy with Vancouver Financial Results and Outlook, followed by Stephen with our current business updates in infectious diseases. David will then review our clinical progress in oncology and rare diseases. And I will come back quickly for a close on our key value drivers before Q&A. The Moderna team delivered a great third quarter, generating $1.3 billion in revenues, representing 29% growth year over year. Importantly, this strong commercial performance translated into $200 million in net income for the quarter. We also ended the quarter with a strong balance sheet with $8 billion in cash and investments, reflecting a combination of solid operational and commercial execution, along with a highly successful convertible debt financing. And we continue to demonstrate financial discipline across the company, reducing cash costs by 10% compared to the third quarter of last year. Together, these strong results underscore our ability to deliver strong commercial performance while maintaining financial discipline and strengthening our financial position. During the quarter, we achieved several important milestones across our pipeline and our business. USFD approval of mFluciva, making Moderna's fifth approved product and the first mRNA-based influenza vaccine to reach the market. In Canada, we secured approvals of both mFluciva and mCoFlu yesterday, the local brand name for mCombriax, further expanding our respiratory portfolio internationally. In oncology, we are very proud to present positive phase 3 data for intismaran autogen, are individualized cancer therapy being developed in partnership with Merck. The result demonstrated a significant clinical benefit with a 42% reduction in the risk of recurrence or death in patients with resected melanoma. An additional analysis suggesting an even greater benefit of 49% reduction in the risk of recurrence of death in patients who received at least one dose of intismoran as planned. Importantly, this marked the first combination immunotherapy regimen to demonstrate additional benefits over ketudra alone in the adjuvant melanoma setting. We're presenting a significant milestone for melanoma patients and their families around the world. David will discuss these results in greater detail. We also took an important step to further strengthen our financial position. During the quarter, we raised $3 billion for a 0% convertible no-debt. securing long-term capital on highly attractive terms. After accounting for the purchase of cap calls designed to mitigate potential future dilution and fees, we raised approximately $2.6 billion in net proceeds. These financing strengths are our ability to invest in the growth of oncology business, a key strategic priority for Moderna as we approach candidate important clinical milestones. In global health, Our Ebola vaccine candidate, mRNA-1469, developed in collaboration with CEPI, was selected to advance into Phase II-III following a recommendation from the WHO Technical Advisory Group. I am extremely proud of the performance delivered by the team in Q3. Strong sales growth, profitability, approval and quick launch of flu in the U.S. in Tismoran positive Phase III and the converted financing. I'm also very pleased and happy to welcome back Juan Andres to Moderna Executive Committee. Many of you will remember Juan for his previous time at Moderna, where he played a critical role in building and scaling our global manufacturing network during the pandemic. He also led the scale-out of individualized manufacturing for Intismaran Autogen. He knows our company, our technology and our culture extremely well. As we enter this next phase of Moderna's growth with an expanded commercial portfolio and important opportunities ahead in oncology, having Juan back on the team will be invaluable. I am personally very excited to be working with him again, and I know the entire Moderna team is delighted to welcome him back. With that, I turn to Jamie.
You're reading a preview of the MRNA Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing